GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+21.91%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$154M
AUM Growth
+$154M
(-16%)
Cap. Flow
-$90.9M
Cap. Flow
% of AUM
-59.1%
Top 10 Holdings %
Top 10 Hldgs %
66.56%
Holding
37
New
5
Increased
7
Reduced
9
Closed
10
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$9.88M |
| 2 |
Rezolute
RZLT
|
$9.81M |
| 3 |
Legend Biotech
LEGN
|
$7.52M |
| 4 |
Akero Therapeutics
AKRO
|
$5.54M |
| 5 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$4.98M |
Top Sells
| 1 |
Unicycive Therapeutics
UNCY
|
$48.6M |
| 2 |
Akebia Therapeutics
AKBA
|
$10.9M |
| 3 |
Viridian Therapeutics
VRDN
|
$10.1M |
| 4 |
Merus
MRUS
|
$9.98M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$7.81M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $19.8M | 12.84% | 500,000 +250,000 | +100% | +$9.88M |
|
|
2
Rezolute
RZLT
$619M
| $13.5M | 8.8% | 3,033,462 +2,200,420 | +264% | +$9.81M |
|
3
Amylyx Pharmaceuticals
AMLX
$836M
| $12.8M | 8.34% | 2,000,000 +188,004 | +10% | +$1.21M |
|
|
4
Legend Biotech
LEGN
$6.41B
| $12.4M | 8.08% | 350,000 +211,760 | +153% | +$7.52M |
|
|
ABVX
5
Abivax
ABVX
$6.12B
| $9.88M | 6.42% | 1,291,617 -346,494 | -21% | -$2.65M |
|
6
Neurogene
NGNE
$264M
| $7.26M | 4.72% | 485,859 +14,895 | +3% | +$223K |
|
|
7
Akebia Therapeutics
AKBA
$833M
| $7.23M | 4.7% | 1,985,915 -2,987,925 | -60% | -$10.9M |
|
8
Evolus
EOLS
$494M
| $6.63M | 4.31% | 720,118 -224,625 | -24% | -$2.07M |
|
9
Arcellx
ACLX
$3.85B
| $6.59M | 4.28% | 100,000 +55,000 | +122% | +$3.62M |
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $6.26M | 4.07% | 200,000 -45,272 | -18% | -$1.42M |
|
|
11
Akero Therapeutics
AKRO
$3.74B
| $5.54M | 3.6% | +103,848 | New | +$5.54M |
|
|
JBIO
12
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $4.98M | 3.24% | +498,054 | New | +$4.98M |
|
13
Cytokinetics
CYTK
$4.23B
| $4.96M | 3.22% | 150,000 -220,000 | -59% | -$7.27M |
|
14
Immunovant
IMVT
$2.56B
| $4.19M | 2.73% | 262,176 -112,824 | -30% | -$1.81M |
|
|
15
Unicycive Therapeutics
UNCY
$74M
| $3.8M | 2.47% | 796,558 -10,183,442 | -93% | -$48.6M |
|
|
16
KalVista Pharmaceuticals
KALV
$678M
| $3.65M | 2.38% | 323,170 -691,197 | -68% | -$7.81M |
|
17
Taysha Gene Therapies
TSHA
$797M
| $3.47M | 2.25% | +1,500,000 | New | +$3.47M |
|
|
DBVT
18
DBV Technologies
DBVT
$264M
| $3.43M | 2.23% | +374,679 | New | +$3.43M |
|
19
Zura Bio
ZURA
$133M
| $3.33M | 2.16% | 3,170,194 | – | – |
|
|
UPB
20
Upstream Bio, Inc. Common Stock
UPB
$923M
| $3.29M | 2.14% | 300,000 | – | – |
|
21
Context Therapeutics
CNTX
$75.4M
| $3.07M | 2% | 4,683,711 | – | – |
|
|
CNTA
22
Centessa Pharmaceuticals
CNTA
$2.25B
| $2.96M | 1.92% | 225,000 +75,298 | +50% | +$989K |
|
23
Scholar Rock
SRRK
$3.14B
| $2.18M | 1.42% | +61,607 | New | +$2.18M |
|
24
ProMIS Neurosciences
PMN
$28M
| $1.28M | 0.83% | 2,645,128 | – | – |
|
25
Pliant Therapeutics
PLRX
$101M
| $986K | 0.64% | 850,000 | – | – |
|